Free Trial
NASDAQ:CRVS

Corvus Pharmaceuticals (CRVS) Stock Price, News & Analysis

Corvus Pharmaceuticals logo
$5.58 +0.29 (+5.44%)
As of 03:52 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Corvus Pharmaceuticals Stock (NASDAQ:CRVS)

Key Stats

Today's Range
$5.22
$5.64
50-Day Range
$3.73
$5.43
52-Week Range
$2.54
$10.00
Volume
468,075 shs
Average Volume
800,468 shs
Market Capitalization
$415.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
Consensus Rating
Buy

Company Overview

Corvus Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
60th Percentile Overall Score

CRVS MarketRank™: 

Corvus Pharmaceuticals scored higher than 60% of companies evaluated by MarketBeat, and ranked 449th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Corvus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Corvus Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Corvus Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Corvus Pharmaceuticals are expected to grow in the coming year, from ($0.63) to ($0.49) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Corvus Pharmaceuticals is -5.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Corvus Pharmaceuticals is -5.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Corvus Pharmaceuticals has a P/B Ratio of 5.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    16.50% of the float of Corvus Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Corvus Pharmaceuticals has a short interest ratio ("days to cover") of 8.9.
  • Change versus previous month

    Short interest in Corvus Pharmaceuticals has recently decreased by 2.12%, indicating that investor sentiment is improving.
  • Dividend Yield

    Corvus Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Corvus Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.50% of the float of Corvus Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Corvus Pharmaceuticals has a short interest ratio ("days to cover") of 8.9.
  • Change versus previous month

    Short interest in Corvus Pharmaceuticals has recently decreased by 2.12%, indicating that investor sentiment is improving.
  • News Sentiment

    Corvus Pharmaceuticals has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Corvus Pharmaceuticals this week, compared to 3 articles on an average week.
  • Search Interest

    Only 1 people have searched for CRVS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Corvus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Corvus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,893,541.00 in company stock.

  • Percentage Held by Insiders

    28.50% of the stock of Corvus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    46.64% of the stock of Corvus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Corvus Pharmaceuticals' insider trading history.
Receive CRVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRVS Stock News Headlines

HC Wainwright Analysts Raise Earnings Estimates for CRVS
Research Analysts Set Expectations for CRVS FY2028 Earnings
“Sell Nvidia before earnings”
Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.tc pixel
See More Headlines

CRVS Stock Analysis - Frequently Asked Questions

Corvus Pharmaceuticals' stock was trading at $5.35 on January 1st, 2025. Since then, CRVS stock has increased by 4.3% and is now trading at $5.5780.

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released its earnings results on Thursday, August, 7th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.03.
Read the conference call transcript
.

Corvus Pharmaceuticals (CRVS) raised $75 million in an IPO on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

Corvus Pharmaceuticals' top institutional shareholders include Orbimed Advisors LLC (9.62%), Foresite Capital Management VI LLC (2.32%), Perceptive Advisors LLC (1.93%) and Geode Capital Management LLC (2.00%). Insiders that own company stock include Peter A Thompson, Richard A Md Miller, William Benton Jones, Leiv Lea and Linda Grais.
View institutional ownership trends
.

Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Corvus Pharmaceuticals investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), Advanced Micro Devices (AMD), ADMA Biologics (ADMA), Rockwell Medical (RMTI), Axcelis Technologies (ACLS) and Protagonist Therapeutics (PTGX).

Company Calendar

Last Earnings
8/07/2025
Today
8/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CRVS
CIK
1626971
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$21.00
Low Price Target
$11.00
Potential Upside/Downside
+168.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$62.29 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-28.61%
Return on Assets
-18.05%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.91
Quick Ratio
8.91

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.08 per share
Price / Book
5.16

Miscellaneous

Outstanding Shares
74,514,000
Free Float
53,278,000
Market Cap
$415.64 million
Optionable
Optionable
Beta
0.42

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:CRVS) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners